🧠 Intracerebral hemorrhage – a type of stroke - is a condition for which no approved treatment exists. In this video, world-renowned expert Prof Robin Lemmens talks about the work Bioxodes is doing to develop a drug candidate for this often deadly disease. Here are some of the highlights of what he says: 🔺 Intracerebral hemorrhage (ICH) makes up for only 15% of all strokes, but accounts for 40% of all stroke-related deaths. 🔺 In some regions of the world, ICH is much more common, reaching 50% of all strokes, showing its severe impact on public health 🔺 Current options to treat ICH are extremely limited. The only available treatment today is to reduce blood pressure as quickly as possible 🔺 BIOX-101, Bioxodes’s treatment candidate for ICH, is a “highly relevant therapeutic target”. It is important to evaluate BIOX-101 in clinical trials. Prof Robin Lemmens is the Principal Investigator in the Bioxodes Phase 2a clinical study with BIOX-101, and head of the stroke unit at the University Hospitals Leuven, UZ Leuven.